ProQR Therapeutics (PRQR) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

PRQR ProQR Therapeutics

Watchlist

2.0099
-0.0101-0.50%

Trading Apr 24 14:34 ET

163.51MMarket Cap-5359P/E (TTM)

Intraday

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

ProQR Therapeutics Announces Board Nomination and AGM
TipRanksApr 23 07:27 ET
Express News | ProQR Therapeutics NV: Intends to Change Board Structure From Two-Tier Structure to One-Tier Board
Moomoo 24/7Apr 23 07:15 ET
Express News | ProQR Nominates Martin Maier, Phd to Board and Announces Annual Meeting of Shareholders to Be Held May 22, 2024
Moomoo 24/7Apr 23 07:00 ET
ProQR Highlights Upcoming Presentations on Axiomer RNA Editing at ASGCT 27th Annual Meeting
ProQR Therapeutics NV (Nasdaq: PRQR) today announced it will present new preclinical data for its proprietary Axiomer RNA editing technology platform, including the first preclinical data for its AX-0810 pipeline program for cholestatic diseases targeting NTCP at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, May 7-11, 2024, in Baltimore, Maryland.
GlobeNewswireApr 22 16:31 ET
Leber Congenital Amaurosis Pipeline Insight 2024, Featuring Key Players ProQR Therapeutics, Editas Medicine, Atsena Therapeutics, Applied Genetic Technologies, IVERIC Bio and MeiraGTx
Yahoo FinanceApr 22 07:51 ET
Express News | ProQR Achieves Successful Defense of New Challenge to Its Axiomer™ Ip Portfolio
Moomoo 24/7Apr 19 07:00 ET

Comments

Jaguar8

Apr 23 04:33

$ProQR Therapeutics(PRQR.US)$
NEWS
ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it will present new preclinical data for its proprietary Axiomer™ RNA editing technology platform, including the first preclinical data for its AX-0810 pipelin...

JESSE JAMES8832

Jan 19 20:22

ProQR Therapeutics Highlights New Platform Data From Presentation On Axiomer RNA Editing Technology, Company Says Platform Demonstrates Robust In Vivo Editing Capabilities Reporting Up To 70% Editing

$ProQR Therapeutics(PRQR.US)$

Moomoo AI

Jan 18 20:57

ProQR Therapeutics' short term liquidity and more cash than debt suggest it can manage its debt safely. Its 38% revenue growth is a positive sign, indicating potential for further strong growth.